Obsidian Therapeutics and Galera Therapeutics announced a merger structure backed by a $350 million infusion aimed at advancing their combined tumor-infiltrating lymphocyte (TIL) cell therapy development. The transaction is designed to provide public listing exposure alongside a private placement to support clinical trials and pipeline expansion. The deal positioning is centered on claims that Obsidian’s TIL approach may offer advantages over Iovance Biotherapeutics’ marketed TIL therapy for melanoma. If sustained in clinical data, the combined platform could reshape competitive dynamics in autologous/off-the-shelf-adjacent TIL development. For the sector, the immediate impact is funding and execution capacity—an important signal amid ongoing scrutiny of cell therapy economics, trial timelines, and scale-up requirements.